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Abstract: The Biomolecular Screening Facility (BSF) is a multidisciplinary laboratory created in 
2006 at the École Polytechnique Fédérale de Lausanne (EPFL) to perform medium and high 
throughput screening in life sciences-related projects. The BSF was conceived and developed to 
meet the needs of a wide range of researchers, without privileging a particular biological discipline 
or therapeutic area. The facility has the necessary infrastructure, multidisciplinary expertise and 
flexibility to perform large screening programs using small interfering RNAs (siRNAs) and 
chemical collections in the areas of chemical biology, systems biology and drug discovery. In the 
framework of the National Centres of Competence in Research (NCCR) Chemical Biology, the 
BSF is hosting ‘ACCESS’, the Academic Chemical Screening Platform of Switzerland that provides 
the scientific community with chemical diversity, screening facilities and know-how in chemical 
genetics. In addition, the BSF started its own applied research axes that are driven by innovation in 
thematic areas related to preclinical drug discovery and discovery of bioactive probes.  
Keywords: Academic screening, assay automation, assay development, high-content screening, hits prioritization, hits-to-
leads, phenoytpic assays, target-based assays. 
INTRODUCTION 
 Until recently, screening for bioactive molecules was 
almost exclusively carried out by the pharmaceutical 
industry; however, at the beginning of the 21st century the 
first academic programs were initiated  [1]. It is now widely 
recognized that academic screening centers play an 
important role in drug and biological probe discovery, thanks 
to the valuable multidisciplinary contributions of academic 
researchers. Over the last decade, many universities and 
research units worldwide have integrated screening and early 
drug discovery disciplines to create screening centers or 
facilities following different models according to their 
institutional mandates. 
 Planned during 2005 and started in the spring of 2006 at 
the Life Sciences Faculty of the Ecole Polytechnique 
Fédérale de Lausanne (EPFL), the Biomolecular Screening 
Facility (BSF) was conceived with a long-term vision, 
structured plan, and operating model that was ambitious and 
original in an academic setting at that time. The three main 
criteria in the creation of the BSF are described as follows: 
Fulfilling Needs 
 The platform was designed and constructed according to 
the needs and ideas of researchers from different disciplines, 
with various life science applications and objectives in mind. 
The platform does not privilege any particular biological 
discipline or therapeutic area and performs screens in (but 
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not limited to) the areas of cancer research  [2, 3], 
neurobiology  [4, 5], and metabolic and infectious 
diseases  [6] for researchers interested in drug discovery, 
chemical biology and systems biology. This ‘generic’ and 
flexible concept was extended to the type of screening assays 
and the nature of compounds to be tested. The BSF performs 
a large variety of assays in 96 and 384 well plate format for 
in vitro biochemical target-based and cellular assays, 
including image-based phenotypic assays (High Content 
Screening [HCS]). Regarding the compounds that are 
screened, our researchers objectives prompted us to select 
and acquire libraries of synthetic chemicals, natural products 
and synthetic small interfering RNA duplexes, (siRNAs) for 
gene knockdown screens up to the genome scale. 
Experienced Staff 
 We hired technicians and scientists with previous pharma-
ceutical or biotechnological industrial experience in order to 
avoid the time-consuming learning process for establishing 
industrial practices in compound management, assay validation, 
automation and statistical data analysis. Moreover, for a broader 
coverage of different disciplines with a small team, we selected 
platform members with multidisciplinary skills. Thanks to the 
professional level and commitment of the staff, the BSF has 
been able to handle a large variety of projects and deliver the 
first results from screening campaigns from early in its 
activities, while continuing to construct and develop the 
platform infrastructure  [2, 4]. 
Applied Research at the Screening Platform 
 To perform screening in an academic setting, it was 
essential to innovate by developing an independent applied 
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research program. The earliest example of this was the 
development of an in-house system for information and data 
management (LIMS) that was planned from the creation of the 
BSF. Our customized LIMS gives us important advantages in 
terms of complete control of the system, quality of screening 
operations, and provides us with operating cost savings, as there 
is no need to pay license fees for third-party software. 
 The BSF handles incoming project proposals according 
to a precise management workflow (Fig. 1) that enables 
collaborative interaction between the platform staff and the 
external project members. In addition to our fundamental 
activities, the BSF also has an educational role, and the 
research axes of the platform seek to innovate the screening 
process through new approaches and technologies. It is our 
aim, and we believe our mission as academics, to contribute 
to the development of future technologies and methodologies 
in this evolving field through selected, specifically funded, 
research projects. 
PROGRAMMED DEVELOPMENT OF THE 
SCREENING PLATFORM 
 The BSF mission is to perform chemical and siRNAs 
screens and to have open access  [7] for training users and 
for participating in educational programs at the EPFL School 
of Life Sciences. The platform was designed to fulfill the 
specific needs of researchers and was constructed in two 
phases during the period 2006-2008; today the center 
occupies about 230 m2. One of the major challenges during 
the initial phase was to design an integrated robotic 
workstation that was flexible enough to perform all the 
major automated tasks in the lab, from traditional compound 
management and in vitro screening experiments to whole 
genome siRNA transfections/cellular screens. During the 
second phase, a second workstation was designed to increase 
the screening capacity, in particular for in vitro target-based, 
chemical screens. Recently, an integrated platform based 
around a non-contact acoustic dispenser was acquired, 
completing the high-end fluidic handling equipment. 
 After the platform was validated by delivering results 
from screening campaigns for local EPFL researchers and 
the associated community, we extended our activities 
through interaction with national networks, initiatives and 
programs. In 2007 the BSF platform was integrated in the 
Swiss Initiative for Systems Biology  [8], allowing us to 
specialize in large-scale gene knock-down screens using 
whole genome siRNAs collections, principally through 
informative screening by imaging assays  [9-11]. More 
recently, the BSF is currently hosting ‘ACCESS’, an 
academic chemical screening platform for Switzerland, in 
the framework of the National Centre of Competences in 
Research (NCCR)-Chemical Biology, led by the University 
of Geneva and the EPFL  [12]. 
The NCCR for Chemical Biology 
 The main mission of the NCCR ‘Chemical Biology – 
Visualization and Control of Biological Processes Using 
Fig. (1). Screening projects workflow at the screening platform BSF/ACCESS. Project proposal submissions are followed by a series of 
planned steps, where the initial evaluation of users questions and needs is critical for defining the type of interaction and support provided by 
the BSF. The initial part of the collaboration between the project and BSF teams is essential for a smooth transfer of knowledge and tools 
between the two groups, and is invaluable for successful assay validation and subsequent screening operations. Consulting, advising, 
educating and training are among the most time consuming and valued tasks of the screening platform team. Additional BSF support to our 
partners includes assistance for grant requests and co-application for funding collaborative programs. 
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Chemistry’ is to use chemical tools to obtain a better 
understanding of life at the molecular level  [13]. Until now, 
few technologies could characterize the countless 
biochemical activities that constitute a living cell in detail. In 
the NCCR Chemical Biology, chemists, biochemists, 
physicists and cell biologists are developing innovative 
techniques based on small molecules and proteins to obtain 
new information about cellular processes and to control them 
in situ. These new tools will be applicable to various 
biological phenomena, such as visualizing the activity of 
selected proteins during cell division and investigating how 
the cell membrane controls protein activity. The NCCR is 
also engaged in establishing a platform for academic 
chemical screening in Switzerland (ACCESS), which aims to 
develop a new generation of bioactive molecules. 
ACCESS 
 One of the goals of this national project is to establish a 
platform that provides the Swiss scientific community with 
access to chemical diversity, screening facilities and know-
how in chemical genetics. The ACCESS platform, 
centralized at the EPFL-BSF, is fast becoming a focal point 
of the NCCR and will enable the scientific community in 
Switzerland to benefit from the enormous possibilities 
offered by chemical biology. 
 The BSF actively participated in the preparation of this 
NCCR project, in particular in the elaboration of the plan to 
further develop the existing platform into a national 
specialized center for chemical screening. The main 
objectives and developments carried out during the first three 
years (2011-2013) of this national project are described in 
Table 1. 
The BSF-ACCESS Chemical Collection Approaches 
100’000 Compounds 
 Thanks to its important infrastructure, the BSF has been 
performing screens since 2006 and handling collections of 
up to 130’000 siRNAs and 65’000 chemical compounds. 
About 15’000 of these small molecules are available for 
screening by our whole community of researchers. The 
remaining collections (50’000 compounds, mostly GPCRs 
and kinase-targeted libraries) are available for projects with 
specific partnering agreements between the research groups 
and the suppliers of these focused chemical libraries. The 
BSF ‘generic set’ of 15’440 chemicals that we make 
available to every screening project is essentially composed 
of the Hit-Finder collection (from Maybridge) of 14’400 
compounds representing drug-like diversity and the NINDS 
II collection (from Microsource Discovery Systems) of 
1’040 bioactive compounds. To provide our users with 
access to a larger chemical diversity, we expanded the 
existing BSF collections by designing, selecting and 
purchasing the sets and sub-collections described in Table 2. 
 The first ACCESS collection (the Chemically Diverse 
set) was designed and selected using an innovative approach 
that led to the selection of about 54’000 commercially 
available compounds covering the known chemical space. 
‘Escape from flatland’  [14] has been suggested as being 
beneficial for clinical success of compounds in the drug 
discovery pipeline. 
 Although molecular shape is recognized as an important 
property in drug discovery, often little attention is paid to 
this feature during the creation of compound collections for 
screening  [15]. Using visualization tools developed in-
house, we applied an innovative molecular shape-based 
approach for the analysis of chemical space in the design of 
the ACCESS screening collection (Fig. 2). In addition to the 
shape criteria, the classic and widely accepted descriptors 
(essentially those included in the rule of five) were 
introduced to evaluate whether they yield a more 
pharmacologically relevant chemical space. The design of 
the ‘Diverse Screening Collection for Chemical Biology’, 
that included molecular shape as a descriptor, resulted in an 
enrichment of three-dimensional molecules. This set is 
composed of nearly 54’000 compounds in 8'611 clusters, 
yielding an average redundancy of six compounds per 
cluster. 
Collecting Compounds from Academic Laboratories and 
Establishing Compound Management Procedures 
 Another goal of ACCESS is to create a screening library 
containing chemical compounds collected from Swiss 
academic labs that will be stored and managed at the EPFL. 
The strategy for collecting these compounds has been 
defined and pilot tests have been performed with the 
members of the NCCR that donated the first sets of 
compounds. We validated our strategic approach for 
collecting these unique synthetic molecules after establishing 
standard operating procedures and guidelines for proper 
handling, transfer and tracking of donated compounds. The 
diagram shown in Fig. (3) briefly summarizes these 
procedures, including some aspects of the global compound 
management strategy. 
Table 1. NCCR-Chemical Biology-ACCESS: Goals and Current Status of Developments 
 
CHEMICAL LIBRARIES  
• Building the ACCESS chemical collection: Increasing the available chemical diversity at the BSF; currently about 95’000 small molecules 
• The Swiss chemical collection:  A strategy for collecting compounds from academic synthetic chemistry labs has been developed and validated  
INSTRUMENTAL INFRASTRUCTURE 
• Compound management and quality control: Definition and validation of the compound management instrumental infrastructure and 
standard operating procedures for handling and controlling the chemical integrity of chemicals 
• ACCESS screening outstation: An ACCESS antenna has been opened at the University of Geneva with selected screening instrumentation 
including an automated screening microscope allowing faster progression of in house HCS projects  
ENLARGING THE COMMUNITY OF BSF COLLABORATORS THROUGH ACCESS 
• Various chemical screens have been performed for the NCCR-Chem Biol partners and pilot projects are progressing towards lead optimization  
• Opening the platform to Swiss academic and non profit-research institutions 
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A Successful Pilot Screening Campaign 
 One of the first screening campaigns performed in the 
context of the NCCR Chemical Biology has been used by 
ACCESS to validate the new instruments, new chemical 
libraries and procedures (Fig. 4). The primary assay for this 
screen was an in vitro enzymatic assay that used a homogenous 
time-resolved fluorescence (HTRF) read-out and aimed to 
discover inhibitors of the enzyme Sepiapterin Reductase (SPR). 
The rational approach from the team of Professor Kai Johnsson 
was based on previous research showing that blocking the 
activity of SPR affects the cellular levels of the molecule  
 
tetrahydrobiopterin (BH4), which is critical for the production 
of neurotransmitters such as serotonin and dopamine. BH4 
deficiency causes similar neurological problems to the side 
effects of sulphonamide drugs. Thanks to the initial ACCESS 
screening of the collection of known drugs (The Prestwick 
Chemical Library) and subsequent validations, the group of 
Professor Johnsson at the EPFL showed for the first time that 
sulphonamides bind to the enzyme that synthesizes BH4. Thus, 
the group’s work showed that sulphonamides interfere with the 
biosynthesis of neurotransmitters, which can account for their 
neurological side effects. It also helps us understand how the 
activity of these drugs relates to their molecular structure, and  
 
Table 2. The BSF/ACCESS Chemical Collections Stored at the BSF (October 2013) 
 
Name of the Set Number of Compounds  Suppliers Comments and Status 
The Chemically diverse set 54’000 
Enamine Chemdiv    
Life Chemicals 
Commercially available chemical space covered with an average 
redundancy of six compounds per cluster. The collection was 
designed using shape as one of the chemical descriptors resulting 
in a diverse collection enriched with 3D structures and sp3 centers. 
Protein-protein interaction 
(PPi) 5’441 Life Chemicals 
This set is composed of compounds chosen by PPi-Machine-
Learning-Method (895) and PPi-Rule-of-four (4546).  
Natural products (NPs) 2’654 Analyticon, InterBioscreen 
These compounds are purified organic molecules from fractionated 
extracts of two sources, plants and bacteria.  
The Prestwick Chemical 
Library (PCL) 1’280 Prestwick Chemicals A set of known bioactive molecules, approved drugs. 
Kinases inhibitors  192 Selleckchem This selected set is composed of 192 kinases inhibitors. 
The natural products-
inspired set About 15’000 Various suppliers 
Currently in progress. Design and selection of a collection of 
synthetic molecules using all commercially available NPs and 
derivatives as reference.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Density map of the 54’000 compounds in the ACCESS subset ‘chemical diverse collection’. The design of a diverse screening 
collection for chemical biology including molecular shape as a descriptor resulted in an enrichment of three-dimensional molecules. 
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suggests ways in which their clinical use could be 
optimized  [16]. 
 This project, which was the first to use the ACCESS 
diverse collection of 54’000 compounds, is currently 
validating the expanded chemical structures from validated 
hits using secondary cellular assays and is progressing 
towards valuable leads. The outcome of this and other 
screening campaigns performed so far has been a useful 
assessment of the value and quality of the collections for the 
discovery of new bioactive chemical entities in chemical 
biology and drug discovery projects. 
Opening the Screening Platform to Swiss Researchers 
 In its current phase the ACCESS-BSF platform is 
opening its access to other Swiss Academic Institutions and 
the NCCR-Chemical Biology has made a call for high  
impact chemical screening proposals within Switzerland. 
After these proposals are evaluated by the ACCESS steering 
committee, the management board of the NCCR will sponsor 
the first selected projects to enter the platform. The selection 
procedure will be based on chemical biology, scientific 
relevance, and feasibility of adapting the proposed validated 
biochemical or biological assay to a high throughput-
screening format. 
Financial Aspects 
 The platform’s instruments have been mainly financed by 
the EPFL, with important contributions by NCCR Chemical 
Biology and SystemsX.ch. The pricing of most screens is 
based on moderate fees for services and consumables, with a 
contribution to instrument maintenance and repair. Some 
projects are carried out in a collaborative framework through 
specific grants that may also cover part of the staffing costs. 
It is our policy to privilege academic projects and industrial  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Overall process for collecting synthetic compounds from academic groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4A). Compound management using an automated storage system. Compounds dissolved at a concentration of 10 mM in dimethyl 
sulfoxide in 2D-bar coded capped tubes (300 uL) are stored at -20°C in an automated store in a controlled low humidity environment. Plated 
compounds are also stored in the system using sealed 1D coded 384 well plates. Compound tracking and inventory is performed by a 
Laboratory Information Management System (LIMS) developed by the BSF. 
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collaborations. So far, services for private companies have 
been limited to access to some instruments (i.e. automated 
microscopes). 
BSF Applied Research and Industrial Collaborations 
 Contribution to the development of new screening 
technologies and approaches is, in our opinion, an important 
mission for screening platforms in an academic environment. 
Indeed, academic screening centers are in an ideal position to 
understand the diverse needs of a large community of 
researchers and to identify topics for further investigation 
that could result in innovative tools and approaches that 
advance the discovery process. We strongly believe that 
screening and drug discovery can only be integrated as 
academic disciplines through active independent research, 
and this is where screening facilities, such as the BSF, have a 
major role to play. 
 Based on our interpretation of the current needs of the 
field and our own areas of scientific expertise, we selected 
the research axes of the BSF to design informative and 
relevant assays and to explore the chemical diversity 
provided by natural sources. 
 Few of the projects in which the BSF has been actively 
involved were purely academic collaborations. One early 
example of an academic project was the development and 
validation of a new high throughput screening (HTS) assay 
for direct unbiased monitoring of telomerase activity without 
post amplification of the resulting DNA products 
(TeloSpot)  [2]. Later on, in another academic collaboration 
involving three partners, we used cyanobacteria extracts to 
screen telomerase inhibitors; after fractionation of active 
extracts, this led to the identification of two sulfoquinovosyl 
diacylglycerol active structures that were further validated 
after chemical synthesis  [3]. 
Industrial Collaborations 
 Most of the research projects involving or led by the BSF 
are collaborations with industrial partners, mainly through 
joint industry-academia projects granted by the Swiss 
Commission for Technology and Innovation (CTI). This is 
illustrated by the two examples described below. 
 In 2010, we started a four partner, CTI-funded, 
collaborative project between Prof. Radtke (EPFL), Dr. 
Turcatti (BSF-EPFL), and the Swiss companies Debiopharm 
and Atheris. This project aimed to identify novel peptides 
that interfere with pathways controlling cell fate as potential 
therapeutic compounds to fight cancer stem cells  [17]. 
During this collaboration, the EPFL performed screens using 
an innovative co-culture cellular assay and in vitro assays 
using Atheris venoms. After fractionation, these yielded 
validated candidates that are currently being optimized by 
the Atheris ‘Reverse-Discovery’ lead optimization platform 
in collaboration with Debiopharm  [18] This project 
illustrates the added value of the multi-partner collaborative 
approach and for the BSF represents the second example of 
the exploration of products from natural sources; in this case, 
peptides with therapeutic potential present in the Atheris 
venoms collections  [19]. 
 Regarding HCS research, the BSF is leading a two year, 
CTI-funded collaboration with LyncéeTec S.A.  [20] (an 
EPFL spin off company that develops instruments for Digital 
Holographic Microscopy [DHM]). In the context of this 
collaboration, we have validated screening applications after 
automating a DHM microscope and optimizing this 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4B). Checking the chemical integrity of chemical compounds using an UHPLC-MS system. To estimate the purity of the whole 
collection within a reasonable time frame, an ultra high performance liquid chromatography system connected to different detectors (Mass 
spectrometer, UV and CAD) was installed and the workflow from data acquisition to data processing has been validated. Hits from screens 
will be systematically analyzed and it is planned to randomly analyze the whole ACCESS collections according to the throughput. 
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technology that enables label-free quantitative cellular 
imaging in cell viability screens  [21]. This technique 
appears to be superior to other label-free interferometric 
microscopy for quantitative cellular analysis, and is unique 
in its suitability for HTS and time-lapse label-free 
imaging  [22]. We are currently developing a series of other 
validated applications, such as screening by imaging of the 
GABA-A ligand-gated chloride channel receptor  [23], 
profiling compounds against cancer cell lines for anti-mitotic 
and anti-proliferative activity, and cellular assays in 
physiologically-relevant 3D matrices. 
FUTURE PROSPECTS 
 The BSF is evolving into a specialized national centre for 
chemical biology that aims to advance selected projects to 
the drug discovery phase. One of the future challenges will 
be to achieve this evolution without detrimental effects on 
less applied areas of research. Our goal is to maintain our 
flexibility to satisfy the diverse needs of academic 
researchers, while simultaneously increasing the number of 
projects aimed at discovery of new chemical probes. 
Moreover, we believe that rather than being incompatible, 
the general and specialized functions of our centre 
complement each other. Opening the platform as a national 
centre significantly increased our activities, therefore our 
limited manpower could result in delays during busy times; 
however, thanks to the NCCR Chemical Biology, two more 
positions have been created, increasing the number of full 
time employees to 6.6. Depending on the success and 
evolution of the centre, further increases in manpower could 
be envisioned. With a few exceptions, staff members are 
employed on a temporary basis, with contracts renewed 
annually up to a maximum of four years, thus, as is the case 
with many academic technological platforms, there is the 
additional challenge of maintaining the high level of 
expertise and know-how acquired over the years. 
 The BSF has some exciting perspectives in view, and we 
foresee a promising future for academic screening in general. 
As our ambitious goals are put into practice, it is possible 
that some plans may be modified or adapted. This may 
require flexibility and support from our institution, in 
particular concerning the status and perception of 
technological platforms that have evolved to become more 
than just services providers. In this respect, we think that the 
research projects started in our laboratories merit attention 
for their significant contributions in the multiple domains 
that involve screening, in particular in early drug discovery. 
For this to continue, researchers should have access to 
academic grants for projects closely related to life sciences 
that target technologies and methodologies, and not only for 
basic biological research. Stronger links between academic 
screening centres and collaborative research efforts are the 
perfect opportunity to make major advances in discovery 
technologies and methodological approaches. 
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